產(chǎn)品展廳收藏該商鋪

您好 登錄 注冊(cè)

當(dāng)前位置:
美國(guó)布魯克海文儀器公司>技術(shù)文章>Nanobrook Omni測(cè)量應(yīng)用案例-15

技術(shù)文章

Nanobrook Omni測(cè)量應(yīng)用案例-15

閱讀:225          發(fā)布時(shí)間:2018-6-19

文獻(xiàn)名: Lipidic Nanoparticles Comprising Phosphatidylinositol Mitigate Immunogenicity and Improve Efficacy of Recombinant Human Acid Alpha-Glucosidase in a Murine Model of Pompe Disease

 

作者Jennifer L.Schneider, Robert K.Dingman, Sathy V.Balu-Iyer 

Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214

 

摘要:Enzyme replacement therapy with recombinant human acid α-glucosidase (rhGAA) is complicated by the formation of anti-rhGAA antibodies, a short circulating half-life, instability in the plasma, and limited uptake into target tissue. Previously, we have demonstrated that phosphatidylinositol (PI) containing liposomes can reduce the immunogenicity and extend plasma survival of factor VIII (FVIII) in a mouse model of hemophilia A. In this article, we investigate the ability of PI liposomes to be used as a delivery vehicle to overcome the issues that complicate therapy with rhGAA. In a murine model of Pompe disease, administration of PI-rhGAA mitigated the immunogenicity of rhGAA, resulting in a significantly lower formation of anti-rhGAA antibodies. PI-rhGAA also showed minimal improvements to the pharmacokinetic parameters and efficacy measures compared to free rhGAA. Overall, these data suggest that PI-rhGAA may have the potential to be a useful therapeutic option for improving the treatment of Pompe disease.

收藏該商鋪

請(qǐng) 登錄 后再收藏

提示

您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~

對(duì)比框

產(chǎn)品對(duì)比 產(chǎn)品對(duì)比 聯(lián)系電話 二維碼 意見(jiàn)反饋 在線交流

掃一掃訪問(wèn)手機(jī)商鋪
010-62081908
在線留言